MedPath

DANA-FARBER CANCER INSTITUTE

🇺🇸United States
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
-
Website
http://www.dana-farber.org/

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Cancer
Interventions
First Posted Date
2018-04-12
Last Posted Date
2021-04-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
17
Registration Number
NCT03495323
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1
Active, not recruiting
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
First Posted Date
2018-04-02
Last Posted Date
2025-02-19
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
5
Registration Number
NCT03485547
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2
Active, not recruiting
Conditions
Breast Cancer
Interventions
Procedure: Stereotactic radiosurgery (SRS)
First Posted Date
2018-03-29
Last Posted Date
2024-08-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
6
Registration Number
NCT03483012
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

Phase 2
Terminated
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2018-03-19
Last Posted Date
2020-08-03
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
4
Registration Number
NCT03469258
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1
Completed
Conditions
Melanoma
Interventions
First Posted Date
2018-03-07
Last Posted Date
2024-07-31
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
6
Registration Number
NCT03455764
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds

Completed
Conditions
Breast Cancer
Interventions
Other: Phone interview
First Posted Date
2018-02-27
Last Posted Date
2021-06-11
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
17
Registration Number
NCT03447886
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2
Terminated
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2018-02-07
Last Posted Date
2025-03-25
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
5
Registration Number
NCT03425331
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma

Not Applicable
Active, not recruiting
Conditions
Breast Cancer
Interventions
Radiation: Radiation Therapy
First Posted Date
2018-02-05
Last Posted Date
2024-11-01
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
400
Registration Number
NCT03422003
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Stanford University Medical Center, Stanford, California, United States

and more 12 locations

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Phase 2
Active, not recruiting
Conditions
Uveal Melanoma
Interventions
First Posted Date
2018-01-31
Last Posted Date
2024-06-25
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
13
Registration Number
NCT03417739
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2018-01-30
Last Posted Date
2025-02-26
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
78
Registration Number
NCT03414684
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

The Stamford Hospital, Stamford, Connecticut, United States

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath